Overall, the application of RAF/MEK/ERK inhibitors contributes to targeted therapy for tumors, and the effect of RAF/MEK/ERK inhibitors facilitates the understanding of RAF mutations in tumor therapy. Here, MAP2K7 is linked to neoplasm.